INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

	<u> </u>
Application Number	08/444,790
Filing Date	May 19, 1995
First Named Inventor	Brockhaus
Art Unit	1646
Examiner Name	Zachary C. Howard
Attorney Docket Number	01017/40451B

## U.S. PATENTS

Examiner Initial	Cite No	Patent Number	Kind Code	Issue Date	Name of Patentee or Applicant of cited Document
	A1				
	A2				

## U.S. PATENT APPLICATION PUBLICATIONS

Examiner Initial	Cite No	Publication Number	Kind Code	Publication Date	Name of Patentee or Applicant of cited Document
	B1				
	B2				

## FOREIGN PATENT DOCUMENTS

Examiner Initial	Cite No	Foreign Document Number	Country Code	Kind Code	Publication Date	Name of Patentee or Applicant of cited Document	English Translation attached YES NO
	C1						
	C2						
	C3						
	C4						
	C5						

## NON-PATENT LITERATURE DOCUMENTS

		11011 THIERT ETERNITURE DOCUMENTS					
Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item					
Initials	No	(book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher,					
		city and/or country where published.					
	D1	ARORA et al., "Differences in Binding and Effector Functions Between Classes of TNF					
		Antagonists," Cytokine 45: 124-131 (2009)					
	D2	FURST et al., "Tumor Necrosis Factor Antagonists: Different Kinetics and/or Mechanisms of Action					
		May Explain Differences in the Risk for Developing Granulomatous Infection," Semin. Arthritis					
		Rheum. 36: 159-167 (2006)					
	D3	MITOMA et al., "Mechanisms for Cytotoxic Effects of Anti-Tumor Necrosis Factor Agents on					
		Transmembrane Tumor Necrosis Factor α-Expressing Cells," Arthr. & Rheum. 58(5): 1248-1257					
		(2008)					
	D4	STRANGFELD et al., "Risk of Herpes Zoster in Patients with Rheumatoid Arthritis Treated with					
		Anti-TNF-α Agents," JAMA 301(7): 737-744 (2009)					

Examiner Signature:	Date Considered:				
EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through a citation					
if not in conformance and not considered. Include copy of this form with next communication to applicant.					

Page 2 of 2

INFORMATION DISCLOSURE			Application Number	08/444,790		
			Filing Date	May 19, 1995		
		BY APPLICANT	First Named Inventor	Brockhaus		
~			Art Unit	1646		
			Examiner Name	Zachary C. Howard		
			Attorney Docket Number	01017/40451B		
	D5	WALLIS et al., "Granulomatous Infectious Diseases Associated with Tumor Necrosis Factor				
		Antagonists," Clin. Inf. Dis. 38: 1261-1265 (2004)				
	D6	WALLIS et al., "Reactivation of Latent Granulomatous Infections by Infliximab," Clin. Inf.				
		Dis. 41(Suppl 2): S1-S5 (2005)				
	D7	WINZOR et al., "Evaluation of Equilibrium Constants from Precipitin Curves: Interaction of				
		$\alpha$ -Crystallin with an Elicited Monoclonal Antibody," Arch. Biochem. Biophys. 268(1): 221-				
		226 (1989)				
	D8	AVIS, Kenneth, Parental Preparations, Remington Pharmaceutical Sciences, Chapter 85,				
		pages 1518-1541 (1985).				
	D9	Center for Drug Evaluation and Research, Guidelines on Sterile Drug Products Produced by				
		Aseptic Processing, Published by the FDA June 1987.				

Examiner Signature:	Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.